People: Maxygen Inc (MAXY.O)
MAXY.O on Nasdaq
2.36USD
22 May 2013
2.36USD
22 May 2013
Price Change (% chg)
$-0.01 (-0.42%)
$-0.01 (-0.42%)
Prev Close
$2.37
$2.37
Open
$2.38
$2.38
Day's High
$2.40
$2.40
Day's Low
$2.36
$2.36
Volume
61,561
61,561
Avg. Vol
75,314
75,314
52-wk High
$6.33
$6.33
52-wk Low
$2.35
$2.35
Summary
| Name | Age | Since | Current Position |
|---|---|---|---|
Isaac Stein |
65 | 2009 | Executive Independent Chairman of the Board |
James Sulat |
62 | 2009 | Chief Executive Officer, Chief Financial Officer, Director |
John Borkholder |
43 | 2011 | General Counsel, Secretary |
Louis Lange |
63 | 2005 | Independent Director |
Kenneth Lee |
64 | 2009 | Independent Director |
Ernest Mario |
74 | 2001 | Independent Director |
Gordon Ringold |
61 | 1997 | Independent Director |
Biographies
| Name | Description |
|---|---|
Isaac Stein |
Mr. Isaac Stein is Executive Independent Chairman of the Board of Maxygen Inc. He has served as the Company’s Chairman of the Board of Directors since June 1998 and as Executive Chairman of the Board of Directors since September 2009, and has been a director since May 1996. Since November 1982, Mr. Stein has been President of Waverley Associates, Inc., a private investment firm. He is a member of and the emeritus Chairman of the Board of Trustees of Stanford University and is a director of American Balanced Fund, Inc., International Growth and Income Fund, Inc. and The Income Fund of America, Inc. (all affiliated with the Capital Group Companies), and Alexza Pharmaceuticals, Inc. He is also a director of the James Irvine Foundation. Mr. Stein received an M.B.A. and J.D. from Stanford University and a B.A. in mathematical economics from Colgate University. |
James Sulat |
Mr. James R. Sulat is Chief Executive Officer, Chief Financial Officer, Director of Maxygen Inc. He has served as the Company’s Chief Executive Officer and Chief Financial Officer since October 2009 and has served as a director since October 2003. From February 2008 to November 2008, Mr. Sulat served as the Chief Financial Officer of Memory Pharmaceuticals Corp., a biotechnology company. From May 2005 to February 2008, Mr. Sulat served as Chief Executive Officer of Memory Pharmaceuticals Corp. Mr. Sulat was Senior Executive Vice President and Interim Chief Financial Officer of R.R. Donnelley & Sons Co., a diversified printing company, from February 2004 until May 2004. From April 2003 to February 2004, Mr. Sulat was Senior Executive Vice President of Moore Wallace Incorporated, a diversified printing company that was acquired by R.R. Donnelley in 2004. From April 1998 to April 2003, Mr. Sulat was Vice President and Chief Financial Officer of Chiron Corporation, a biotechnology company. Mr. Sulat is also a director of Intercell AG and Momenta Pharmaceuticals, Inc., and has previously served as a director of Memory Pharmaceuticals Corp. and Vans, Inc. Mr. Sulat holds a B.S. from Yale University, an M.B.A. from Stanford University and an M.S. in health services administration from Stanford University. |
John Borkholder |
Mr. John M. Borkholder is General Counsel, Secretary of Maxygen Inc., since March 16, 2011. Mr. Borkholder joined Maxygen in November 2005 as Senior Counsel and served as Chief Corporate Counsel & Secretary beginning in March 2008 before being promoted to General Counsel in January 2011. Prior to joining Maxygen, Mr. Borkholder served as an attorney with the law firms of Orrick, Herrington & Sutcliffe LLP and Giancarlo & Gnazzo, P.C. Mr. Borkholder holds a B.A. in philosophy from the University of North Carolina at Wilmington and a J.D. from the University of California, Hastings College of the Law. |
Louis Lange |
Dr. Louis G. Lange, M.D., Ph.D., is Independent Director of Maxygen Inc., since December 2005. Dr. Lange is currently a partner with Asset Management Company, a venture capital firm that he joined in June 2009. Since June 2009, Dr. Lange has also served as a Senior Advisor of Gilead Sciences, Inc. From April 2009 to June 2009, Dr. Lange served as Executive Vice President, Cardiovascular Therapeutics, of Gilead. He was a founder of CV Therapeutics, Inc. and served as its Chairman and Chief Executive Officer from August 1992 until the acquisition of the company by Gilead in April 2009. Dr. Lange has served as a trustee on the University of Rochester Board of Trustees since May 1997 and was a member of the governing body of the Emerging Company Section of the Biotechnology Industry Organization from 1999 to 2009. From 1980 to 1992, Dr. Lange served on the faculty of Washington University School of Medicine, including as Chief of Cardiology at Jewish Hospital in St. Louis, Missouri from 1985 to 1992, and as a full Professor of Medicine from 1990 until 1992. Dr. Lange holds an M.D. from Harvard Medical School and a Ph.D. in biological chemistry from Harvard University. |
Kenneth Lee |
Mr. Kenneth B. Lee, Jr., is Independent Director of Maxygen Inc., since September 2009. He is currently a General Partner with Hatteras Venture Partners, LLC (formerly, BioVista Capital, LLC), which he joined in 2003. From January 2002 to June 2002, Mr. Lee served as President of A.M. Pappas & Associates, an international life sciences venture development company. From 2000 to 2001, Mr. Lee was Managing Director of Ernst & Young LLP’s Health Sciences Corporate Finance Group. From 1982 through 2000, Mr. Lee was a Partner of Ernst & Young LLP. Mr. Lee is also a director of Inspire Pharmaceuticals, Inc. and Pozen, Inc. and has previously served as a director of Abgenix, Inc., OSI Pharmaceuticals and CV Therapeutics, Inc. Mr. Lee also serves as a member of the executive committee of the Board of the North Carolina Biotechnology Industry Organization. Mr. Lee received a B.A. from Lenoir-Rhyne College and an M.B.A. from the University of North Carolina at Chapel Hill. |
Ernest Mario |
Dr. Ernest Mario, Ph.D., is Independent Director of Maxygen Inc., since July 2001. Since August 2007, Dr. Mario has served as the Chairman of the Board and Chief Executive Officer of Capnia, Inc., a privately held pharmaceutical company. From April 2003 to August 2007, Dr. Mario served as the Chairman of the Board and Chief Executive Officer of Reliant Pharmaceuticals, Inc., a privately held pharmaceutical company. Prior to joining Reliant Pharmaceuticals, he was Chairman and Chief Executive Officer of IntraBiotics Pharmaceuticals, Inc., a biopharmaceutical company, and its predecessor Apothogen, Inc. from January 2002 until April 2003. Dr. Mario was the Chairman and Chief Executive Officer of ALZA Corporation, a pharmaceutical company, from 1997 to 2001 and was Co-Chairman and Chief Executive Officer of ALZA Corporation from 1993 to 1997. Prior to joining ALZA, Dr. Mario served as Chief Executive Officer of Glaxo Holdings plc, a pharmaceutical company, from 1989 to 1993, and as Deputy Chairman from 1992 to 1993. Dr. Mario is also a director of Pharmaceutical Product Development, Inc. Celgene Corporation and Boston Scientific Corporation and has previously served as a director of IntraBiotics Pharmaceuticals, Inc. Dr. Mario received a Ph.D. and an M.S. in physical sciences from the University of Rhode Island and a B.S. in pharmacy from the Ernest Mario School of Pharmacy at Rutgers University. |
Gordon Ringold |
Dr. Gordon Ringold, Ph.D., is Independent Director of Maxygen Inc., since September 1997. Since June 2010, Dr. Ringold has served as the Senior Director of the University of California, Santa Cruz, Silicon Valley Initiatives. Since June 2010, Dr. Ringold also has served as the Executive Chairman of Alavita Pharmaceuticals, Inc., a private biotechnology company. Dr. Ringold previously served as the Chairman and Chief Executive Officer of that company from 2005 to June 2010. From 1997 to 2005, Dr. Ringold served as Chairman and Chief Executive Officer of SurroMed, Inc., a biotechnology company focused on novel clinical databases. From March 1995 to February 2000, Dr. Ringold was Chief Executive Officer and Scientific Director of Affymax Research Institute where he managed the development of novel technologies to accelerate the pace of drug discovery. Before serving as Chief Executive Officer of Affymax, Dr. Ringold was the President and Scientific Director of Affymax Research Institute. Dr. Ringold is also a director of Alexza Pharmaceuticals, Inc. Dr. Ringold received a Ph.D. in microbiology from the University of California, San Francisco in the laboratory of Dr. Harold Varmus before joining the Stanford University School of Medicine, Department of Pharmacology. Dr. Ringold also received a B.S. in biology from the University of California, Santa Cruz. |
Basic Compensation
| Name | Fiscal Year Total |
|---|---|
Isaac Stein |
-- |
James Sulat |
679,714 |
John Borkholder |
441,070 |
Louis Lange |
-- |
Kenneth Lee |
-- |
Ernest Mario |
-- |
Gordon Ringold |
-- |
As Of 30 Dec 2011
Options Compensation
| Name | Options | Value |
|---|---|---|
Isaac Stein |
0 | 0 |
James Sulat |
0 | 0 |
John Borkholder |
0 | 0 |
Louis Lange |
0 | 0 |
Kenneth Lee |
0 | 0 |
Ernest Mario |
0 | 0 |
Gordon Ringold |
0 | 0 |
| Name | Shares Traded | Price |
|---|---|---|
BORKHOLDER JOHN M |
2,769 | $2.42 |
BORKHOLDER JOHN M |
1,855 | $2.48 |
SULAT JAMES R |
40,000 | $0.00 |
BORKHOLDER JOHN M |
3,048 | $2.72 |
STEIN ISAAC |
90,000 | $0.00 |
BORKHOLDER JOHN M |
3,048 | $5.90 |
LANGE LOUIS G |
10,000 | $0.00 |
RINGOLD GORDON |
10,000 | $0.00 |
LEE KENNETH B JR |
10,000 | $0.00 |
MARIO ERNEST B |
10,000 | $0.00 |
RINGOLD GORDON |
10,000 | $5.27 |
RINGOLD GORDON |
10,000 | $5.22 |
LEE KENNETH B JR |
3,000 | $5.23 |
MARIO ERNEST B |
10,000 | $0.00 |
LEE KENNETH B JR |
10,000 | $0.00 |
RINGOLD GORDON |
10,000 | $0.00 |
LANGE LOUIS G |
10,000 | $0.00 |
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
